A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure

NCT00294086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Heart Failure

Interventions

DRUG: valsartan 160 mg
DRUG: valsartan 160 mg BID

Sponsor

Novartis